Molecular Subtype-Associated Response to Cyclophosphamide-Epirubicin-Cisplatin Regimen in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Retrospective Single-Center Study.

Cancers (Basel) · 2026 · PMC13256737 · PMID 42279429

Europe PMC DOI

hedged sentence

0.0740

closest p · 1.5× alpha

0.0740

boldest claim

The sentences

showed a trendp = 0.074so close (0.05 < p ≤ 0.1)

Bone metastasis showed a trend toward shorter PFS (HR = 2.43; 95% CI, 0.92–6.41; p = 0.074) but did not reach significance for OS (HR = 2.04; 95% CI, 0.63–6.55; p = 0.233) ( Supplementary Table S3, Supplementary Figure S1A,B ). 3.4.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.